Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

241 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2016-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the CELT ACD® Vascular Closure Device study is to evaluate the safety and effectiveness of the CELT ACD® device to achieve hemostasis of the common femoral artery access site in patients on anticoagulation who are undergoing a percutaneous intervention (PCI) procedure using a 6F sheath.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

InSeal Vascular Closure Device Clinical Study Protocol

NCT01896401

Percutaneous Closure of Artery Access Sites

TERMINATED NA

Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System

NCT03756558

Vascular Closure

COMPLETED NA

Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)

NCT05335525

Vascular Closure Endovascular Procedure Hemostasis +2 more

UNKNOWN

ThrombX Retriever for Acute Ischemic Stroke Trial

NCT05270122

Ischemic Stroke

UNKNOWN NA

InSeal VCD Large Bore Vascular Closure Device Safety and Effectiveness Clinical Study

NCT02628782

Percutaneous Closure of Artery Access Sites

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Disease Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CELT ACD device

The CELT ACD device is a vascular closure device.

Group Type EXPERIMENTAL

CELT ACD

Intervention Type DEVICE

The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.

Manual Compression

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CELT ACD

The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Over 18 years of age.
2. Each patient, or his or her guardian or legal representative, is willing to give informed consent.
3. Clinically indicated for an intra-arterial procedure involving access through the common femoral artery and conducted through an access sheath size of between 6F and 7F inclusive.

Exclusion Criteria

1. Patients with known allergy to any of the materials used in the device.
2. Severe acute non-cardiac systemic disease or terminal illness with a life expectancy of less than one year.
3. Evidence of systemic bacterial or cutaneous infection, including groin infection.
4. Patients suffering with definitive or potential coagulopathy or platelet count \<100,000./µl
5. Use of systemic thrombolytic agents within 24 hours prior to or during the catheterization procedure which cause the concentration of fibrinogen to be \< 100 mg/dl or if post-thrombolytic fibrinogen (in case of thrombolysis within 24 hours or intra-procedural) cannot be measured.
6. Patients in whom an introducer sheath smaller than 6F or greater than 7F have been used.
7. Currently participating in another investigational device or drug study.
8. Patients with severe claudication, iliac or femoral artery diameter stenosis greater than 50%, or previous bypass surgery or stent placement in the vicinity of the access site.
9. If puncture site is via a vascular graft.
10. If a palpable haematoma is observed during the procedure.
11. Patients in whom there is any indication that puncture has been made in the profunda femorals artery or superficial femoral artery, or adjacent to the bifurcation.
12. Patients with a common femoral artery lumen diameter of less than 5 mm.
13. Patients that have any amputation from an access site limb.
14. Patients that have undergone a percutaneous procedure using a vascular closure device for hemostasis within the previous 30 days or using manual/mechanical pressure for hemostasis within the prior 30 days in the same leg.
15. Patients with a systolic blood pressure reading below 90 mmHg.
16. Patients with an active haematoma, arteriovenous fistula, or pseudoaneurysm.
17. Patients with a very superficial artery where the depth from skin to the artery surface at the access site is less than 4 mm.
18. Morbidly obese patients (Body Mass Index \>35kg/m2).
19. Patients with a stent less than or equal to 1 cm of the puncture site that would interfere with placement of the device implant.
20. Patient is know or suspected to be pregnant, or is lactating.
21. Patients in whom there has been an antegrade puncture.
22. Patients in whom there has been difficulty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial wall puncture.
23. Patients who have undergone prior or recent use of an intra-aortic balloon pump through the arterial access site.
24. Patients with uncontrolled hypertension (BP greater than or equal to 180/110mmHg) at time of vascular closure
25. Patients with acute ST-elevation myocardial infarction less than or equal to 48hours before catheterization procedure.
26. Patients with cardiogenic shock (hemodynamic instability requiring intravenous medication or mechanical support) experienced during or immediately post-catheterization.
27. Patients who are unable to ambulate at baseline.
28. Patients known to require an extended hospitalization (e.g. patient is undergoing cardiac surgery).
29. Patient has already participated in the trial.
30. Patient is unavailable for follow up.

\-

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No